The Food and Drug Administration (FDA) has accused drugmakers Novartis AG and Celgene Corp of misrepresenting some of their cancer drugs by overstating how effective they are at targeting tumors without having proof to support the claims.
According to Reuters, the FDA wrote letters to each company requesting that they stop using advertising that violates the agency’s guidelines. The FDA told Novartis that the manufacturer was misleading when it promoted how their cancer drug Gleevec worked well for a particular patient. The agency said the promotion falsely implied that the drug would work just as well for other patients.
Heath regulators wrote to Celgene about its breast cancer drug, Abraxane as well. They told the drugmaker it had violated guidelines by broadening the drug’s uses and omitting safety information that was published in a paper displayed at the American Society of Clinical Oncology meeting on 2010.
If you’ve been harmed by a dangerous drug, contact Sokolove Law for a free legal consultation and to learn about your options.